Online Exclusives

Online Exclusives

Researchers Develop a New Agent for Hemophilia A

Researchers have developed a new bypassing agent that mimics the pro-clotting activity of factor V Leiden and gives the clotting process more time to...

ASH Joins Other Medical Organizations in Statement on Immigration Executive Order

In a joint statement, the American Society of Hematology, the American Association for Cancer Research, the Association of American Cancer Institutes, the American Society...

Generic Imatinib as Cost-Effective as First-Line Treatment for CML

This year, generic imatinib will be introduced in the United States and Europe and, according to a study published in the Journal of the...

Less-Frequent Dosing of Zoledronic Acid Maintains Efficacy, Improves Safety for Myeloma Patients

Recent guidelines suggest that zoledronic acid – a third-generation aminobisphosphonate used to treat certain bone disease, including multiple myeloma (MM) – should be administered...

Europe’s CHMP Recommends Nivolumab for Hodgkin Lymphoma

Europe’s Committee for Medicinal Products for Human Use recommended nivolumab for the treatment of patients with relapsed/refractory classic Hodgkin lymphoma (cHL) after autologous hematopoietic...

Is Fracking Linked to Increased Risk of Developing Leukemia and Lymphoma?

Carcinogens involved in the controversial practice of hydraulic fracturing (also known as “fracking”) have the potential to contaminate air and water in nearby communities,...

ABIM Extends Suspension of MOC Program’s Practice Assessment Component

The American Board of Internal Medicine (ABIM), which has come under a great deal of fire over the past two years from the internal...

From ASH 2014: Novel CART Approach for the Treatment of Hodgkin Lymphoma

SAN FRANCISCO — For the 10 to 15 percent of patients who relapse or are refractory to first-line therapy, novel approaches with modified chimeric...

European Commission Approves Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma

The European Commission approved nivolumab for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) after autologous hematopoietic cell transplantation (HCT) and treatment with brentuximab vedotin. The...

Patients With Chronic Myeloid Leukemia Have Life Expectancy Approaching that of General Population

With the introduction of tyrosine kinase inhibitors (TKIs) and allogeneic hematopoietic cell transplantation (alloHCT), the life expectancy of patients with chronic myeloid leukemia (CML)...
Advertisement

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.